KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Other Non-Current Liabilities: 2010-2025

Historic Other Non-Current Liabilities for Ionis Pharmaceuticals (IONS) over the last 10 years, with Sep 2025 value amounting to $28.8 million.

  • Ionis Pharmaceuticals' Other Non-Current Liabilities fell 94.65% to $28.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.8 million, marking a year-over-year decrease of 94.65%. This contributed to the annual value of $51.9 million for FY2024, which is 89.89% down from last year.
  • Ionis Pharmaceuticals' Other Non-Current Liabilities amounted to $28.8 million in Q3 2025, which was down 51.27% from $59.1 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $538.1 million for Q3 2024, and its period low was $6.9 million during Q4 2021.
  • For the 3-year period, Ionis Pharmaceuticals' Other Non-Current Liabilities averaged around $348.6 million, with its median value being $510.2 million (2023).
  • In the last 5 years, Ionis Pharmaceuticals' Other Non-Current Liabilities grew by 4.95% in 2024 and then crashed by 94.65% in 2025.
  • Over the past 4 years, Ionis Pharmaceuticals' Other Non-Current Liabilities (Quarterly) stood at $6.9 million in 2021, then reached $513.7 million in 2023, then tumbled by 89.89% to $51.9 million in 2024, then plummeted by 94.65% to $28.8 million in 2025.
  • Its last three reported values are $28.8 million in Q3 2025, $59.1 million for Q2 2025, and $55.7 million during Q1 2025.